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The aim of this study is to systematically collect all published preclinical non-human animal lit-
erature on depression to provide an unbiased overview of existing knowledge. A systematic
search will be carried out in PubMed and Embase. Studies will be included if they use non-
human animal experimental model(s) to induce or mimic a depressive-like phenotype. Data that
will be extracted include the model or method of induction; species and gender of the animals
used; the behavioural, anatomical, electrophysiological, neurochemical or genetic outcome
measure(s) used; risk of bias/quality of reporting; and any intervention(s) tested. There were no
exclusion criteria based on language or date of publication. Automation techniques will be used,
where appropriate, to reduce the human reviewer time. Meta-analyses will be conducted if fea-
sible. This broad systematic review aims to gain a better understanding of the strengths and
limitations of current approaches, models and outcome measures used. This study aims to pro-
vide insights into factors affecting the efficiency of model induction and the efficacy of inter-
vention. Here, we outline the protocol for a systematic review and possible meta-analysis of
the preclinical studies modelling depression-like behaviours and phenotypes in animals.
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1 | BACKGROUND
1.1 | What is already known about this disease/
model/intervention? Why is it important to do this
review?
Depression is a mental illness characterized by “low mood, loss of
interest and pleasure or loss of energy.”1 It is the leading cause of disa-
bility in the world2 and is currently the brain disorder with the highest
financial cost in Europe.3 The number of people diagnosed with
depression worldwide is estimated to be 400 million.4 Depression
places a huge burden on patients and poses a great cost to healthcare
systems and governments. The rate of remission with antidepressant
medication is, at best, 70% and may only be achieved after several
levels of intervention.5,6 Despite decades of investigation into
depression, little is known about the biological mechanisms underpin-
ning the disease.7,8 With better understanding of the mechanisms
causing depression, the development of novel and more reliable
treatments might be possible. There is solid rationale that further
investigation into the mechanisms and factors that contribute to the
development of depression is needed. This is a highly important area
to tackle, both from a clinical and a preclinical perspective.
Preclinical investigations contribute significantly to understanding
the mechanisms underlying depression, which can, in turn, inform
treatment development and increase translational success of clinical
research. One example of this contribution is the systematic review
and meta-analysis of antidepressants for the treatment of stroke.9
Analysis of the evidence in the preclinical animal literature informed
key aspects of the trial design in the subsequent FOCUS trial.10 Pre-
clinical experiments have the ability to model and dissect important
mechanisms of depression and therefore provide insights into the
neurobiology of the disorder.11 Preclinical experiments can also
investigate the safety and efficacy of proposed treatments prior to
exposure in human cohorts.12 The knowledge from preclinical
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investigations can aid prevention research, translating findings into
the best and earliest interventions for the human disease, which are
top research priorities recently identified by an MQ: Transforming
Mental Health report.13
Due to the sheer volume of preclinical investigations of depres-
sion, it is difficult to achieve an overview of what is already known
and to assess the marginal contribution of new research.23 In this
context, a systematic review of the existing preclinical literature could
provide an unbiased, collective overview of existing knowledge and
allow the additional contribution of new research to be assessed. It
could also provide better understanding of the laboratory methods
used to induce the condition, the range of outcome measures used to
assess depression phenotypes and the variables that might impact
the efficacy of different treatments.14 The findings from this system-
atic review and meta-analysis may also contribute to the refinement
of methods used in animal investigations of depression, reducing the
distress caused to animals by substitution with equally informative
methods of lower severity, and contribute to the optimisation of the
numbers of animals used in depression research by informing well-
founded power calculations.
What is meant by an experimental non-human animal model of
depression? An experimental model in preclinical non-human animal
neuropsychiatric research is defined as including both a dependant
variable (an outcome measurement) as well as an independent varia-
ble (model induction or manipulation).15 We differentiate between
3 broad experimental designs within the animal depression literature
and anti-depressant drug literature:
1. Studies which compare a control group to a group of animals that
receive a lesion (model induction) on an outcome measure. These
studies may also have a drug arm.
2. Studies which only compare a “lesion” group of animals to a
group of lesioned animals that receive a drug intervention. Once
a lesion method has been sufficiently established (known to be
valid and reliable), experimenters know a lesion will induce a
depressive-like phenotype.
3. Studies which use an outcome measure to assess animals who
receive a drug intervention. Once an outcome measure has been
established (known to be valid and reliable), experimenters know
an outcome measure can reliably measure a depressive-like
phenotype.
As a starting point, in order to be thorough, we will look at
experiments that investigate the differences between a control group
and a lesion or model group. This will provide a basis for characteris-
ing a depression model. In these experiments, investigators are
directly manipulating a variable intended to produce a depressive-like
phenotype and measuring the effects of this manipulation on a given
outcome measure. These experiments may or may not include the
presence of a drug group/arm.
On this basis, we will characterize all the known models/lesions.
From this, drug interventions that have been tested on known models
can be characterized. Secondly, the known outcome measures will be
extracted from the control vs model investigations. Once the most
commonly used outcome measures are known, there is further scope
for characterizing the studies that investigate drug interventions with
known outcome measures. We aim to unpick these different experi-
ment design types and evaluate the evidence from all of these
(Table 1).
2 | OBJECTIVES OF THIS SYSTEMATIC
REVIEW
2.1 | Specify the disease/health problem of interest
We will investigate how depression is modelled in vivo. Depression is
defined as specified in the DSM-IV-R under the clinical diagnoses of
“Depression,” “Major Depressive Disorder (MDD) (Single Episode or
Recurring),” “Dysthymia (Persistent Depressive Disorder),” “Depres-
sive Disorder Due to General Medical Condition,” “Other Specified
Depressive Disorder” and/or “Unspecified Depressive Disorder.” This
includes depression at any life stage in any gender. In preclinical mod-
elling of depression, some methods induce depressive-like behaviour
as a single manifestation rather than modelling the full range of fea-
tures associated with the clinical diagnoses. Therefore, any model
that attempts to mimic one or several major symptoms of depression
in an animal model will be considered.
Not all aspects of the human condition can be modelled. Some typi-
cally modelled phenotypes in non-human animals include anhedonia and
disturbances in sleep and/or food consumption. However, we will not
exclude the possibility that novel research has attempted to investigate
other aspects not previously modelled in non-human animals, and there-
fore, there are no restrictions on what phenotypes are modelled, only
that they are present in the manifestation of the condition in humans.
2.2 | Specify the population/species studied
All preclinical studies on any animal species at any stage of develop-
ment will be included.
2.3 | Specify the intervention/exposure
This study will investigate any mode of inducing depressive behaviour or
a model that seeks to mimic the human condition or symptoms of depres-
sion using genetic, surgical, pharmacological, developmental or beha-
vioural interventions or a combination of interventions. We will include
models induced acutely, chronically, genetically or through a combination
of these methods. We will also consider experiments where the efficacy
of a treatment or intervention is tested in such models.
TABLE 1 Stage of the project at time of protocol submission
Stage of process Started Completed
Preliminary searches Yes Yes
Piloting study selection Yes Yes
Formal screening with final search criteria Yes Yes
Data extraction from included papers No No
Quality assessment No No
Data analysis No No
Manuscript writing No No
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2.4 | Specify the control population
Studies will be included in this review if they include a suitable control,
defined as a cohort of animals that have not been exposed to the method
of inducing depressive-like behaviour that was used to create the depres-
sive model. The control cohort may have received an appropriate equiva-
lent, for example, sham surgery instead of lesion or placebo without the
active ingredient. For studies that investigate treatment efficacy, a suitable
control is defined as a cohort of animals that have had the same exposure
to model the disorder as those that are given a treatment but has not
been exposed to the treatment tested and may instead receive a placebo
in an equivalent route of administration. For studies investigating drug
intervention on an outcome measure, a suitable control is defined as a
cohort of animals that are not exposed to the drug treatment and may
instead receive a placebo in an equivalent route of administration.
2.5 | Specify the outcome measures
2.5.1 | Primary outcome measure
The primary outcome measure is behavioural outcome measures of
animal studies inducing depressive-like phenotype.
2.5.2 | Secondary outcome measures
Secondary outcomes include anatomical outcomes, electrophysiologi-
cal outcomes, neurochemical outcomes and prevalence of reporting
of measures to reduce risk of bias.
2.5.3 | Tertiary outcome measures
Tertiary outcomes include drug efficacy; inter-rater agreement in the
application of the inclusion criteria; and sample size, genomic, prote-
omic and metabolomic outcomes.
2.6 | Research Questions
1. How are animal models of depression induced?
2. What type of outcome measures are assessed in animal models
of depression?
3. How precise and accurate are the outcome measures at assessing
induced behaviours?
4. To what extent are the outcomes measured in animal models rel-
evant to the endpoints investigated in human trials?
5. How efficacious are different drug interventions in reducing
observed manifestations in in vivo animal models?
3 | METHODS
3.1 | Search and study identification
3.1.1 | Identify literature databases to search
Both PubMed and Embase will be searched.
3.1.2 | Define electronic search strategies
See attached for PubMed search terms (Appendix S1, Supporting Infor-
mation) and Embase search terms (Appendix S2). The animal search filter
used for both PubMed and Embase search strings was developed by the
Systematic Review Centre for Laboratory Animal Experimentation, Rad-
boud University Medical Centre (SYRCLE). Reference: A step-by-step
guide to systematically identify all relevant animal studies. Marlies Lee-
naars, Carlijn R Hooijmans, Nieky van Veggel, Gerben ter Riet, Mariska
Leeflang, Lotty Hooft, Gert Jan van der Wilt, Alice Tillema, Merel Ritskes-
Hoitinga. Laboratory Animals. Vol 46, Issue 1, pp. 24 - 31. First published
date: January-01-2012. 10.1258/la.2011.011087
3.1.3 | Identify other sources for study identification
Relevant recent reviews will be identified via an additional PubMed
search, and the reference list will be searched for any primary
research articles that were not identified with the search.
3.2 | Study selection procedure
3.2.1 | Define screening phases (e.g. pre-screening based
on title/abstract, full-text screening, both)
PubMed and Embase search results will be downloaded to EndNote
or Reference Manager 12; duplicates will be removed and the full
text of articles retrieved where available using the inbuilt feature.
Screening Phase 1: Title and abstracts retrieved from PubMed
and Embase will be screened.
Screening Phase 2: Full-text papers will be screened concurrently
with data extraction.
3.2.2 | Specify number of observers per screening phase:
method of screening
3.2.2.1 | Phase 1
A machine learning approach is proposed to assist with the screening
phase for inclusion and exclusion criteria. A seed set of papers will be
screened by 2 independent human screeners upon which the
machine learning algorithm can be trained. Any discrepancies will be
resolved by a third human screener. We will pilot the most promising
approaches in the context of an ongoing collaboration where we are
developing machine learning tools for systematic review. The proto-
col for this approach is under development and will be uploaded to
the CAMARADES website (camarades.info).
Pilot testing of the machine learning algorithm: A random sample of
2000 papers from the overall 70 365 studies identified with the search
string was screened for suitability of inclusion by 2 independent
reviewers. The decision from the 2000 papers (included or excluded)
were used, along with title and abstract, as training sets for several dif-
ferent machine learning algorithms developed by collaborators in the
Systematic Living Information Machine (SLIM) consortium. Based on the
preliminary sensitivity and specificity analyses and data from a similar
project testing the same algorithms using a neuropathic pain
dataset,16,17 an estimated Work Saved over Sampling at 95% recall level
(WSS@95% = (TN + FN/N) − 0.5) of above 50% will easily be achieved.
Using this approach can reduce the screening workload by at least an
estimated 50%, reducing the number of papers needed to be screened
by 2 independent human reviewers to less than 35 183 papers.
Quality assessment: A small sub-section of the papers, included
and excluded papers, that the machine learning algorithm classifies
will be checked by a human screener to ensure the performance of
the algorithm.
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Validation: We will validate the machine learning techniques for
screening by sampling; as opposed to having 2 human screeners manually
screen every record. A randomly selected proportion of records that are
included and excluded by the algorithm will be double checked by human
screeners to ensure the gold standard is maintained. We will continuously
monitor the articles screened by the machine learning algorithm by sam-
pling. The machine learning approaches must reach comparable levels to
human screening gold standard of at least 95% sensitivity, after which the
machine learning algorithm that is maximized for specificity will be chosen.
3.2.2.2 | Phase 2
Two independent screeners are responsible for full-text analysis and
data extraction, with the aid of machine learning and text mining
tools where appropriate, for example, risk of bias classification. A
third independent screener will resolve any discrepancies.
3.3 | Study selection criteria
3.3.1 | Type of study design
3.3.1.1 | Inclusion criteria
Any article providing primary data of an animal model of depression or
depressive-like phenotype with an appropriate control group (specified
above).
3.3.1.2 | Exclusion criteria
Review article, editorials, case reports, letters or comments, confer-
ence or seminar abstracts, studies providing primary data but not
appropriate control group.
3.3.2 | Type of animals/population
3.3.2.1 | Inclusion criteria
Animals of all ages, sexes and species, where depression-like pheno-
type intended to mimic the human condition have been induced.
Including animal models where depressive-like phenotypes are
induced in the presence of a comorbidity (e.g. obesity or cancer).
3.3.2.2 | Exclusion criteria
Human studies and ex vivo, in vitro or in silico studies. Studies will be
excluded if authors state an intention to induce or investigate only anxiety
or anxious behaviour. Studies will be excluded if there is no experimental
intervention on the animals (e.g. purely observational studies).
3.3.3 | Type of intervention
3.3.3.1 | Inclusion criteria
All studies that claim to model depression or depressive-like pheno-
types in animals. Studies that induce depressive behaviour or model
depression and that also test a treatment or intervention (prior or
subsequent to model induction), with no exclusion criteria based on
dosage, timing or frequency.
3.3.3.2 | Exclusion criteria
Studies that investigate treatments or interventions, but no depres-
sive behaviour or model of depression is induced (e.g. toxicity and
side-effect studies).
3.3.4 | Outcome measures
3.3.4.1 | Inclusion criteria
Studies measuring behavioural, anatomical and structural, electro-
physiological, histological and/or neurochemical outcomes and where
genomic, proteomic or metabolomic outcomes are measured in addi-
tion to behavioural, anatomical, electrophysiological, histological or
neurochemical outcomes.
3.3.4.2 | Exclusion criteria
Where metabolic outcome measures are the primary outcome measure
of a study. Where genomic, proteomic, metabolic or metabolomic out-
comes are the sole outcome measures in a study, they will be excluded.
3.3.5 | Language restrictions
3.3.5.1 | Inclusion criteria
All languages (using automated translations where required).
3.3.5.2 | Exclusion criteria
None.
3.3.6 | Publication date restrictions
3.3.6.1 | Inclusion criteria
All publication dates.
3.3.6.2 | Exclusion criteria
None.
3.3.7 | Other
3.3.7.1 | Inclusion criteria
Studies must investigate methods or models that induce depressive
phenotype/s in vivo, or authors must claim that they investigate a
model of depression.
3.3.7.2 | Exclusion criteria
Studies claiming to induce only anxiety behaviour or a model of anxi-
ety. In cases where both models of anxiety and depression are investi-
gated, the study will be included, and only the depression-related data
will be extracted. In the case of data duplication (2 or more papers
reporting the same data), the paper reporting the smallest dataset or
fewest outcomes will be excluded. Studies will be excluded if they
model aspects of bipolar disorder, manic symptoms, obsessive-
compulsive behaviours, panic disorder or psychotic symptoms.
3.3.8 | Order of priority exclusion criteria per screening
phase
Selection phase 1: screening based on title and abstract
1. Article must be primary research article (excluding reviews, com-
ments or letters).
2. Exclude studies on humans.
3. Exclude ex vivo, in vitro or in silico investigations.
4. Exclude study if no depressive behaviour or model of depression
has been induced.
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Selection phase 2: full text screening
1. The above criteria from selection phase 1.
2. Exclude if no appropriate outcome is measured.
3. Exclude if no appropriate control group.
4. Where sufficient data cannot be extracted and authors do not
respond to requests for required information.
5. Exclude the study with the least information in the case of multi-
ple publications describing the same work.18
4 | STUDY CHARACTERISTICS TO BE
EXTRACTED
4.1 | Study meta-data
The first author, corresponding author, year, title, journal name,
source of funding and DOI will be extracted.
4.2 | Study design characteristics
The number of animals in the experimental and control groups will be
extracted. If the number of animals is given as a range, the most con-
servative estimate will be extracted. The category of experimental
design of the study will be extracted (1. Control vs model induction,
2. Model vs drug, 3. Testing drug on outcome measure).
4.3 | Animal model characteristics
The species, strain, sex (male or female), age and/or weight of animal
will be extracted.
4.4 | Method of model induction/intervention
characteristics
For studies that induce a model of depression, the method used to
induce depressive-like behaviour will be extracted as well as the
duration of the model induction. The category of type of model
induction will be extracted (i.e., genetic, surgical, pharmacological,
developmental or behavioural model induction or a combination of
interventions). We will extract information about whether models
were induced acutely or chronically or both. If applicable, the follow-
ing information will be extracted for the method of model induction:
the dosage of intervention given, route of delivery, mode of delivery
and how long the intervention was given for. The length of time
between model induction and outcome measurement will be
extracted as well as the length of time between the model induction,
any treatment and outcome measurement. For studies with several
methods of model induction given, data from all time points will be
extracted along with details of each method of model induction.
The information regarding outcome measures described below will
be extracted both from experiments describing the induction of a model
of depression and from those describing the efficacy of drugs in such
models.
4.4.1 | Outcome measures
1. Summary outcome data for each group (mean), including whether
variance is reported as SD or SEM and the number of animals
per group.
2. Details of the outcome measure (e.g. the sub-type or name of
the outcome measure and, e.g. in the case of food restriction, the
length of time the animal was restricted for).
3. The number of times the outcome measure was assessed.
4. The number of different outcome measures the animal was
tested on.
5. The category of the behaviour or biomarker the outcome meas-
ure is measuring (e.g. anhedonia, sleep or weight loss, markers of
oxidative stress)
6. Any measures taken before the disease model induction will be
extracted. The details of the before-and-after comparison will be
extracted.
7. Has an appropriate outcome measure been selected for use?
Studies that induce a depression model and investigate the effect
of a subsequent drug intervention should select a suitable test to
measure an outcome (e.g. an outcome measure that does not rely
on the same mechanism/behaviour as behaviour that might be
affected by side-effects of a given drug).
4.4.2 | Treatment characteristics
The following information regarding the treatments tested will be
extracted: the dosage of treatment given, route of delivery, mode of
delivery, how long the treatment was given for. The length of time
between the administration of the treatment and outcome measurement
will be extracted as well as the length of time between the model induc-
tion and any treatment given if applicable. This information will be
extracted regardless of whether an experiment simply assesses an out-
come measure for a given drug treatment or if an experiment has
induced a model of depression and tests a drug treatment.
4.4.3 | Other
The number of excluded animals will be extracted, and the reason for
their exclusion, if reported, will be extracted.
5 | RISK OF BIAS & STUDY QUALITY
5.1 | Criteria to assess the internal validity of
included studies
An adjusted CAMARADES checklist will be used to assess risk of bias,
including the following criteria:
1. Publication in a peer-reviewed journal.
2. Reporting of random allocation.
3. Reporting of blinding of the conduct of the experiment.
4. Reporting of blinded assessment of outcome.
5. Use of comorbid animals (refers to animals where depression is
investigated in the presence of another medical condition, e.g.
stroke or diabetes).
6. Reporting of a sample size calculation.
24 of 27 BANNACH-BROWN ET AL.
7. Reporting of compliance with animal welfare regulations.
8. Reporting of a potential conflict of interest.
9. Reporting of exclusions of animals.
10. Whether a study protocol is available dated before the experi-
ments began.19
We will report the median number of study checklist items
scored and the interquartile range.
6 | COLLECTION OF OUTCOME DATA
6.1 | Methods for data extraction/retrieval
1. Numerical data will be extracted from the full text of publications
(mean, SD or SEM, P values (exact P -value where possible) and
group sample size).
2. In studies where data are presented only graphically, the soft-
ware Universal Desktop Ruler, or a similar tool, will be used to
extract the data into numerical values. For certain PDF presenta-
tions, it may be possible to use data mining approaches to extract
these data.
3. If any data are missing, the corresponding authors will be
contacted.
4. In the absence of a response from authors (we will allow
2 months to reply with a follow-up email sent after the 1st
month), data will be excluded from analysis.
If the screeners or extractors consider that 2 sources may
describe the same data, we will contact the authors seeking clarifica-
tion. If we receive no response, we will include only the most recent
data source.
7 | DATA ANALYSIS/SYNTHESIS
7.1 | Data gathering and combination
All data will be gathered and entered in the CAMARADES-SyRF data-
base. We will provide a qualitative summary along with several sepa-
rate meta-analyses, where feasible.
7.2 | How the decision as to whether a meta-
analysis is appropriate will be made
Based on pilot analyses of a random sample of 2000 from the overall
70 365 studies identified with the search string, approximately 15%
of the total records are expected to be relevant to the research ques-
tion and included in subsequent meta-analyses. This is similar to pre-
vious systematic reviews in models of psychiatric disorders
conducted at CAMARADES where about 10% to 15% of the studies
were included in the analysis. We expect high heterogeneity between
studies due to differences in the study designs; therefore, a meta-
analysis is proposed to investigate sources of this heterogeneity.
8 | IF A META-ANALYSIS SEEMS FEASIBLE/
SENSIBLE
8.1 | Effect measure to be used
Mean, SD or SEM and group sample size will be extracted for all outcome
measures for both experimental and control groups to calculate pooled
effect size. Where a single control group serves multiple intervention
groups, the size of the control group used in the meta-analysis will be
adjusted by dividing it by the number of intervention groups it serves. If
the number of animals is presented in a range, the most conservative esti-
mate will be extracted (e.g. if presented as n = 6–12, we will consider
n = 6). P values, exact P value where possible, will be extracted from pri-
mary analyses between model and control and intervention and model in
order to conduct P-curve analysis.
Categorical or qualitative information relating to the outcome
measures, such as the behavioural measure or the symptom the
model is trying to elucidate, will be extracted into a text/comment
field or into a form drop-down menu.
A decision will be made once the data has been extracted as to which
effect size is the most appropriate to use. As most outcome measures are
continuous variables, and outcome measures are not likely to be meas-
ured on the same scale, Normalized Mean Difference (NMD) effect sizes
will be calculated where possible. This effect size calculation will be used
where an appropriate “sham” or “control” group is present20 or where it is
possible to impute the outcome in a “normal” animal. If the data are
unsuitable for calculating NMD, Standardized Mean Difference (SMD) will
be used. NMD and SMD will be calculated using the equations outlined in
Vesterinen and colleagues.20
8.2 | Statistical model of analysis
The data extracted will in all likelihood cover different species, ages
and sexes, as well as different study designs and models of induction.
Therefore, the true effect size is likely to differ between studies, and
a random effects model will be used.21
Statistical analyses will be performed using Stata, Statistical Soft-
ware (College Station, TX: StataCorp LP).
8.3 | Statistical methods to assess heterogeneity
Cochran’s Q will be used for assessing heterogeneity; Q is used to
calculate the excess variance (Q–k, where k is the degrees of free-
dom). A P value can be calculated for Q, giving an indication of
whether all studies share a common effect size (P < 0.05) or not
(P > 0.05). I2 will be used to report heterogeneity as this describes
the proportion of observed variance that reflects true differences in
effect size between studies.18
8.4 | Specify which study characteristics will be
examined as potential sources of heterogeneity (sub-
group analysis)
Meta-regression will be used to investigate the impact of different
study characteristics on the outcome, where the effect estimate
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(NMD or SMD) is the dependent variable. Categorical variables will
be transformed into dummy variables. Where there are sufficient
data, a multivariate meta-regression will be used for both model
induction and drug models. At least 10 independent comparisons per
covariate investigated are required.21 If there are insufficient data for
multivariate meta-regression, univariate analysis will be used, requir-
ing a total of at least 25 independent comparisons.
8.5 | Model induction model
Sub-groups analyses:
1. Species of animals (mice vs rats vs etc. vs all)
2. Sex of animals (male vs female vs mixed)
3. Type of animal model
4. Method of model induction (e.g. developmental, genetic, phar-
macological, lesion or combination)
5. The outcome measure(s) investigated (behavioural, electrophysi-
ological, neurochemical, anatomical)
6. Number of times the outcome assessment was measured (once
vs several)
7. The time from model induction to time of outcome assessment
8. Randomisation (yes/no)
9. Blinding:
a. Allocation concealment (yes/no)
b. Assessment of outcome (yes/no)
10. Source of funding (public vs industry)
A separate model will be used to investigate the effect of drug
intervention on outcomes.
8.6 | Drug model
Sub-group analyses:
1. Drug Treatment or Intervention.
2. Method of model induction (e.g. developmental, genetic, phar-
macological, lesion or combination), if applicable.
3. The outcome measure(s) investigated (behavioural, electrophysi-
ological, neurochemical, anatomical).
4. Treatment or intervention dose.
5. Treatment or intervention route.
6. Number of times the treatment or intervention is administered.
7. Time the treatment is given in relation to model induction
(investigated separately per treatment, pre- or post-model
induction).
8. Time the treatment is given in relation to time of outcome
assessment.
9. Randomisation (yes/no).
10. Blinding:
a. Allocation concealment (yes/no)
b. Assessment of outcome (yes/no)
11. Source of funding (public vs industry)
Sensitivity analyses will be performed to assess how missing data
from study characteristics and effect size might have affected the
results. This will be presented in the form of a summary table.
8.7 | Correction for multiplicity of testing
Where there are more than 2 groups being compared in a univariate
model, we will use the Holm-Bonferroni correction for multiplicity of
testing.
8.8 | Method for assessment of risk of
publication bias
Risk of publication bias analyses will be assessed using funnel plot
assessment, P-curve analysis and Egger’s regression. Trim and fill
analysis will be used to identify potentially missing studies. Analyses
will be carried out using SigmaPlot and STATA software package
(StataCorp LP; SYSTAT Software Inc).
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